In healthcare and pharmaceuticals, AI-driven technologies are revolutionizing drug discovery and clinical trials, significantly reducing costs and accelerating development processes.
Australian researchers have developed an innovative artificial intelligence tool called PSICHIC (PhySIcoCHemical) that decodes protein-molecule interactions without requiring expensive 3D structures. This AI model effectively screens new drug candidates and performs selectivity profiling, enhancing the efficiency of drug discovery.
Comment
byu/Big_Extreme_8210 from discussion
inbiotech
Published in Nature Machine Intelligence, the study demonstrates PSICHIC’s ability to distinguish the functional effects of compounds on the human body, a breakthrough led by Dr. Lauren May from the Monash Institute of Pharmaceutical Sciences.
Researchers at the University of Canterbury are leveraging digital twin technology to optimize mechanical ventilation. By creating digital replicas of patient information, they can predict the optimal settings for lung ventilation, potentially saving significant costs in intensive care units.
Comment
byu/Fit-Construction-888 from discussion
inbiotech
Professor Geoff Chase highlighted that reducing ventilation time by just one day could save New Zealand approximately $10 million annually. Personify Care and Novari Health have partnered to enhance patient engagement through integrated referral management and rehabilitation pathways.
This collaboration aims to launch in Canada and the United Kingdom, with a fully interoperable offering planned for Australia and New Zealand.
GNQ Insilico’s proprietary platform leverages AI and quantum computing to create digital twins of human patients. These digital twins simulate drug interactions at the cellular level, improving the design and efficiency of clinical trials.
Comment
byu/Fit-Construction-888 from discussion
inbiotech
By predicting drug behavior before human trials, GNQ’s platform reduces costs and increases success rates in drug development. Their recent success in simulating an infertility drug on digital twins underscores the potential of AI in personalized medicine.
At the DIA Global conference, experts discussed the integration of AI and real-world data to transform clinical trials. As highlighted by Ariel Berger of Evidera, disease models and trial simulators optimize trial parameters, reducing time and cost.
John Van Hoy from Thermo Fisher Scientific emphasized AI’s role in discovering novel drug targets, optimizing label expansion, and enhancing return on investment. Additionally, patient-centric studies using social networks provide insights into patient experiences, leading to more effective clinical trials.
Comment
byu/conradthegray from discussion
insingularity
The integration of AI and advanced technologies in drug discovery and clinical trials is reshaping the pharmaceutical landscape. These innovations lower costs and improve the efficiency and success rates of developing new treatments, marking a significant advancement in healthcare.
By leveraging AI, Australia is poised to lead in the global effort to bring more effective and affordable healthcare solutions to the market.
For more news and trends, visit AI News on our website.
